Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.49 |
| ▸ | CNR2 | P34972 | 3/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTPA | Q15257 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PLEC | Q15149 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5057732 | 0.95 | CNR1 (0.44) | CNR1CNR2CASP1SCN5ASCN9A | |
| SCHEMBL5064791 | 0.88 | CNR1 (0.56) | CNR1CNR2CASP1PARP1TSHR | |
| SCHEMBL5058769 | 0.84 | CNR1 (0.47) | CNR1CNR2TP53 | |
| SCHEMBL5057364 | 0.83 | CNR1 (0.51) | CNR1CNR2TSHRTP53 | |
| SCHEMBL5064769 | 0.82 | CNR1 (0.49) | CNR1CNR2ALDH1A1TSHRTP53 | |
| SCHEMBL5064695 | 0.82 | CNR1 (0.53) | CNR1CNR2PARP1TSHRTP53 | |
| SCHEMBL5054098 | 0.79 | CNR1 (0.45) | CNR1CNR2ALDH1A1TSHRTP53 | |
| SCHEMBL5057665 | 0.77 | CNR1 (0.51) | CNR1CNR2ALDH1A1TP53PLEC | |
| SCHEMBL5057572 | 0.76 | CNR1 (0.37) | CNR1CNR2ALDH1A1TP53 | |
| SCHEMBL5057771 | 0.73 | CNR1 (0.46) | CNR1CNR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | CNR1, CNR2, FAAH | CNR1 1/4885CNR2 2/4885CASP1 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.